Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's dis… Read more
Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Total Assets
Latest total assets as of September 2025: $7.40 Million USD
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) holds total assets worth $7.40 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Telomir Pharmaceuticals, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Telomir Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (September 2024)
Telomir Pharmaceuticals, Inc. Common Stock's total assets of $7.40 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Telomir Pharmaceuticals, Inc. Common Stock's current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2021.
- Cash Position: Cash and equivalents constituted 95.6% of total assets in 2024, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of Telomir Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Telomir Pharmaceuticals, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Telomir Pharmaceuticals, Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Telomir Pharmaceuticals, Inc. Common Stock is currently not profitable relative to its asset base.
Telomir Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.51 | 1.74 | 0.05 |
| Quick Ratio | 17.51 | 1.74 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.98 Million | $ 442.07K | $ -937.28K |
Telomir Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Telomir Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.06 |
| Latest Market Cap to Assets Ratio | 19.40 |
| Asset Growth Rate (YoY) | -72.3% |
| Total Assets | $1.32 Million |
| Market Capitalization | $25.69 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Telomir Pharmaceuticals, Inc. Common Stock's assets at a significant premium ( 19.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Telomir Pharmaceuticals, Inc. Common Stock's assets decreased by 72.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Telomir Pharmaceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $1.32 Million | -72.26% |
| 2023-09-30 | $4.77 Million | +9696.36% |
| 2022-09-30 | $48.73K | -11.40% |
| 2021-09-30 | $55.00K | -- |